Story
US Senate Blocks Bill to Restrict Congressional Stock Trading

Summary
Legislation designed to impose new limits on stock trading by members of the U.S. Congress has been blocked in the Senate after failing to secure enough votes to advance, according to reports.
A legislative effort to place new restrictions on stock trading by members of the U.S. Congress was blocked in the Senate on Wednesday, failing to gain the necessary support to proceed toward a final vote. The measure's failure stalls a push to address concerns about potential conflicts of interest among lawmakers.
Procedural Vote Halts Bill
According to a Reuters report, the bill did not advance after Democrats declined to provide enough votes to move the measure forward in the chamber. The vote was a procedural step required to bring the legislation to the Senate floor for full debate and a potential final vote on its passage.
Without sufficient support to overcome this hurdle, the bill cannot proceed further in the legislative process at this time. This effectively halts the current effort to reform ethics rules surrounding lawmakers' financial activities.
AdContext and Implications
The proposed legislation was part of a broader, often bipartisan, push to tighten rules governing how members of Congress and their families can invest. Concerns have been raised for years about the potential for lawmakers to use non-public information gained through their official duties for personal financial enrichment.
Proponents argue that stricter limits, such as banning individual stock ownership or requiring blind trusts, are necessary to ensure public trust and prevent conflicts of interest. The failure of this bill means that the existing rules, primarily based on the disclosure requirements of the STOCK Act of 2012, will remain in place.
Read next
More on Stocks
Praxis Options See Large Bullish Bet Ahead of Two FDA Decisions
A significant options trade on Praxis Precision Medicines suggests a trader is positioning for a substantial stock move ahead of two key FDA drug approval decisions slated for late 2026 and early 2027.

General Mills Appoints COO Dana McNabb as CEO to Succeed Jeff Harmening
The consumer goods company named 27-year veteran Dana McNabb its next chief executive, effective Jan. 1, as it navigates high inflation and competition from private-label brands.

Helsinki Benchmark Index Slips on Industrial and Financial Sector Weakness
Finland's OMX Helsinki 25 index closed down 0.55% on Wednesday, dragged lower by losses in the telecommunications, industrial, and financial sectors.

BEL 20 Index Falls to One-Month Low on Sector-Wide Weakness
Belgium's benchmark BEL 20 index fell 0.73% on Wednesday, hitting a new one-month low. The decline was driven by losses in the technology, financials, and consumer goods sectors, with Warehouses de Pauw NV leading the laggards.